title: Idarucizumab for the Reversal of Dabigatran.
authors.affiliation: Department of Emergency Medicine, Rush University Medical Center, Chicago, IL. Electronic address: MichaelGottliebMD@gmail.com.
authors.forename: Michael
authors.initials: M
authors.lastname: Gottlieb
authors.affiliation: Department of Emergency Medicine, Mount Sinai Hospital, Chicago, IL.
authors.forename: Basem
authors.initials: B
authors.lastname: Khishfe
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000931:Antidotes / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000991:Antithrombins / Q000378:metabolism*; D017321:Clinical Trials, Phase I as Topic; D000069604:Dabigatran / Q000037:antagonists & inhibitors*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000931:Antidotes; D000991:Antithrombins; C000594745:idarucizumab; D000069604:Dabigatran